Cerebral Gliomas

  • Justin Cohen
  • Sergui Bannykh
  • Joshua Breunig
  • Moise Danielpour
Living reference work entry


The majority of hemispheric gliomas in children are low-grade non-infiltrating entities (Pollack 1994). Many features distinguish these tumors from their adult counterparts including histologic appearance, distribution, incidence, and biological behavior. Owing to advances in genetic technology, we have seen dramatic increase in understanding the role of causative genetic mutations and dependence on developmental pathways in oncogenesis and maintenance of pediatric gliomas. In the coming years, continued advancement in understanding of and age-related features in biological behavior, including development and maintenance of these tumors, may lead to development of more rational treatments offering greater survival with decreased morbidity (Schwartzentruber et al. 2012; Zhang et al. 2013; Rohle et al. 2013; Parsons et al. 2008; Frattini et al. 2013; Verhaak et al. 2010; Baker et al. 2015).


  1. Adams JH et al (1988) An introduction to neuropathology, 2nd edn. Churchill Livingstone, EdinburghGoogle Scholar
  2. Appalla D, Depalma A, Calderwood S (2016) Mammalian target of rapamycin inhibitor induced complete remission of a recurrent subependymal giant cell astrocytoma in a patient without features of tuberous sclerosis complex. Pediatr Blood Cancer 63(7):1276–1278PubMedCrossRefPubMedCentralGoogle Scholar
  3. Artico M, Cervoni L, Celli P, Salvati M, Palma L (1993) Supratentorial glioblastoma in children: a series of 27 surgically treated cases. Childs Nerv Syst 9(1):7–9PubMedCrossRefPubMedCentralGoogle Scholar
  4. Au KS, Williams AT, Roach ES et al (2007) Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med 9(2):88–100PubMedCrossRefPubMedCentralGoogle Scholar
  5. Baker SJ, Ellison DW, Gutmann DH (2015) Pediatric gliomas as neurodevelopmental disorders. Glia 64(6):879–895PubMedPubMedCentralGoogle Scholar
  6. Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG (2008) Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol 67(9):878–887PubMedCrossRefPubMedCentralGoogle Scholar
  7. Beni-Adani L, Gomori M, Spektor S, Constantini S (2000) Cyst wall enhancement in pilocytic astrocytoma: neoplastic or reactive phenomena. Pediatr Neurosurg 32(5):234–239PubMedCrossRefPubMedCentralGoogle Scholar
  8. Berger MS, Keles GE, Geyer JR (1992) Cerebral hemispheric tumors of childhood. Neurosurg Clin N Am 3(4):839–852PubMedPubMedCentralCrossRefGoogle Scholar
  9. Berhouma M (2010) Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon’s perspective. World J Pediatr 6(2):103–110PubMedCrossRefPubMedCentralGoogle Scholar
  10. Bouffet E, Perilongo G, Canete A, Massimino M (1998) Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 30(6):319–329PubMedCrossRefPubMedCentralGoogle Scholar
  11. Brat DJ, Cagle PT, Dillon DA, Hattab EM, McLendon RE, Miller MA, Buckner JC (2015) Template for reporting results of biomarker testing of specimens from patients with tumors of the central nervous system. Arch Pathol Lab Med 139(9):1087–1093PubMedCrossRefPubMedCentralGoogle Scholar
  12. Broniscer A, Gajjar A (2004) Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist 9(2):197–206PubMedCrossRefPubMedCentralGoogle Scholar
  13. Broniscer A, Baker SJ, West AN et al (2007) Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol 25(6):682–689PubMedCrossRefPubMedCentralGoogle Scholar
  14. Bruce DA, Shut L, Sutton LN (1990) Supratentorial brain tumors of children. In: Youmans JR (ed) Neurological surgery, 3rd edn. W. B. Saunders, PhiladelphiaGoogle Scholar
  15. Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, …, Zuccaro J (2014) Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genet 46(5):451Google Scholar
  16. Burkhard C, Di Patre PL, Schüler D, Schüler G, Yasargil MG, Yonekawa Y, …, Ohgaki H (2003) A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg 98(6):1170–1174PubMedCrossRefPubMedCentralGoogle Scholar
  17. Butler D, Jose B, Summe R, Paris K, Bertolone S, Patel CC, …, Lindberg R (1994) Pediatric astrocytomas: the Louisville experience: 1978–1988. Am J Clin Oncol 17(6):475–479PubMedCrossRefPubMedCentralGoogle Scholar
  18. Campbell JW, Pollack IF, Martinez AJ, Shultz B (1996) High-grade astrocytomas in children: radiologically complete resection is associated with an excellent long-term prognosis. Neurosurgery 38(2):258–264PubMedCrossRefPubMedCentralGoogle Scholar
  19. Carter M, Nicholson J, Ross F, Crolla J, Allibone R, Balaji V, …, Ellison D (2002) Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer 86(6):929–939PubMedPubMedCentralCrossRefGoogle Scholar
  20. Cin H, Meyer C, Herr R, Janzarik WG, Lambert S, Jones DT, …, Bender S (2011) Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 121(6):763–774PubMedCrossRefPubMedCentralGoogle Scholar
  21. Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, …, Heideman RL (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol 13(3):317–323PubMedPubMedCentralCrossRefGoogle Scholar
  22. Crist WM, Kun LE (1991) Common solid tumors of childhood. N Engl J Med 324(7):461–471PubMedCrossRefPubMedCentralGoogle Scholar
  23. Cuccia V, Zuccaro G, Sosa F, Monges J, Lubienieky F, Taratuto AL (2003) Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst 19(4):232–243PubMedPubMedCentralGoogle Scholar
  24. Daumas-Duport C, Scheithauer B, O’Fallon J, Kelly P (1988) Grading of astrocytomas: a simple and reproducible method. Cancer 62(10):2152–2165PubMedCrossRefPubMedCentralGoogle Scholar
  25. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, …, Louis DN (2011) BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 6(3):e17948PubMedPubMedCentralCrossRefGoogle Scholar
  26. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 48(4):403–407PubMedCrossRefPubMedCentralGoogle Scholar
  27. Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, …, Biegel JA (2010) Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 12(7):621–630PubMedPubMedCentralCrossRefGoogle Scholar
  28. Duffner PK, Burger PC, Cohen ME, Sanford RA, Krischer JP, Elterman R, …, Martin P (1994) Desmoplastic infantile gangliogliomas: an approach to therapy. Neurosurgery 34(4):583–589PubMedGoogle Scholar
  29. Ellison DW, Kocak M, Figarella-Branger D, Felice G, Catherine G, Pietsch T, …, Grundy RG (2011) Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 10(1):1Google Scholar
  30. Elousrouti LT, Lamchahab M, Bougtoub N, Elfatemi H, Chbani L, Harmouch T, …, Riffi AA (2016) Subependymal giant cell astrocytoma (SEGA): a case report and review of the literature. J Med Case Rep 10(1):1Google Scholar
  31. Erlandsson A, Enarsson M, Forsberg-Nilsson K (2001) Immature neurons from CNS stem cells proliferate in response to platelet-derived growth factor. J Neurosci 21(10):3483–3491PubMedCrossRefGoogle Scholar
  32. Farwell JR, Dohrmann GJ, Flannery JT (1977) Central nervous system tumors in children CNS tumors in children. Cancer 40(6):3123–3132PubMedCrossRefGoogle Scholar
  33. Felix C, Slavc I, Dunn M et al (1995) p53 gene mutations in pediatric brain tumors. Med Pediatr Oncol 25(6):431–436PubMedCrossRefGoogle Scholar
  34. Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, …, Tefft M (1995) Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Children’s Cancer Group. J Clin Oncol 13(1):112–123PubMedCrossRefGoogle Scholar
  35. Fleming AJ, Chi SN (2012) Brain tumors in children. Curr Probl Pediatr Adolesc Health Care 42(4):80–103PubMedCrossRefPubMedCentralGoogle Scholar
  36. Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, …, Corcoran A (2014) Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature Genet 46(5):462–466PubMedPubMedCentralCrossRefGoogle Scholar
  37. Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW, …, Chaplin T (2009) Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 218(2):172–181PubMedCrossRefGoogle Scholar
  38. Fouladi M, Jenkins J, Burger P, Langston J, Merchant T, Heideman R, …, Gajjar A (2001) Pleomorphic xanthoastrocytoma: favorable outcome after complete surgical resection. Neuro Oncol 3(3):184–192PubMedPubMedCentralCrossRefGoogle Scholar
  39. Franz DN (2013) Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. Biologics 7:211–221PubMedPubMedCentralGoogle Scholar
  40. Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, …, Danussi C (2013) The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 45(10):1141–1149PubMedPubMedCentralCrossRefGoogle Scholar
  41. Gajjar A, Bowers DC, Karajannis MA, Leary S, Witt H, Gottardo NG (2015) Pediatric brain tumors: innovative genomic information is transforming the diagnostic and clinical landscape. J Clin Oncol 33:2986–2998PubMedPubMedCentralCrossRefGoogle Scholar
  42. Giannini C, Scheithauer BW, Burger PC, Brat DJ, Wollan PC et al (1999) Pleomorphic xanthoastrocytoma: what do we really know about it? Cancer 85:2033–2045PubMedCrossRefGoogle Scholar
  43. Giannini CPW, Louis DN, Liberski P (2007) Pleomorphic xanthoastrocytoma. In: Louis DN, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system. IARC Press, Lyon, pp 22–24Google Scholar
  44. Guillamo JS, Créange A, Kalifa C, Grill J, Rodriguez D, Doz F, …, Wolkenstein P (2003) Prognostic factors of CNS tumours in neurofibromatosis 1 (NF1). Brain 126(1):152–160PubMedCrossRefGoogle Scholar
  45. Gutman RL, Peacock G, Lu DR (2000) Targeted drug delivery for brain cancer treatment. J Control Release 65(1):31–41PubMedCrossRefGoogle Scholar
  46. Hirsch JF, Sainte Rose C, Pierre-Kahn A, Pfister A, Hoppe-Hirsch E (1989) Benign astrocytic and oligodendrocytic tumors of the cerebral hemispheres in children. J Neurosurg 70(4):568–572PubMedCrossRefGoogle Scholar
  47. Ho CY, Mobley BC, Gordish-Dressman H, VandenBussche CJ, Mason GE, Bornhorst M, …, Devaney JM (2015) A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. Acta Neuropathol 130(4):575–585PubMedCrossRefGoogle Scholar
  48. Hoffman LM, Donson AM, Nakachi I, Griesinger AM, Birks DK, Amani V, …, Handler MH (2014) Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma. Acta Neuropathol 127(5):731–745PubMedPubMedCentralCrossRefGoogle Scholar
  49. Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, Krailo MD, …, Adamson PC (2008) Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children’s Oncology Group Phase I Consortium Study. J Clin Oncol 26(30):4921–4927PubMedPubMedCentralCrossRefGoogle Scholar
  50. Johnson RA, Wright KD, Poppleton H, Mohankumar KM, Finkelstein D, Pounds SB, …, Hogg T (2010) Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466(7306):632–636PubMedPubMedCentralCrossRefGoogle Scholar
  51. Jones C, Baker SJ (2014) Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer 14(10):651–661CrossRefGoogle Scholar
  52. Jones DT, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K, Collins VP (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68(21):8673–8677PubMedPubMedCentralCrossRefGoogle Scholar
  53. Jones DT, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz HJ, …, Fontebasso AM (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genet 45(8):927–932Google Scholar
  54. Jones C, Karajannis MA, Jones DT, Kieran MW, Monje M, Baker SJ, …, Hargrave D (2016) Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol 19(2):153–161Google Scholar
  55. Jozwiak S, Nabbout R, Curatolo P (2013) Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): clinical recommendations. Eur J Paediatr Neurol 17(4):348–352PubMedCrossRefGoogle Scholar
  56. Kepes JJ, Rubinstein LJ, Eng LF (1979) Pleomorphic xanthoastrocytoma: a distinctive meningocerebral glioma of young subjects with relatively favorable prognosis. A study of 12 cases. Cancer 44:1839–1852PubMedCrossRefGoogle Scholar
  57. Kilday JP, Rahman R, Dyer S, Ridley L, Lowe J, Coyle B, Grundy R (2009) Pediatric ependymoma: biological perspectives. Mol Cancer Res 7(6):765–786PubMedCrossRefGoogle Scholar
  58. Kilday JP, Mitra B, Domerg C, Ward J, Andreiuolo F, Osteso-Ibanez T, …, Ellison DW (2012) Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children’s Cancer Leukaemia Group (CCLG), Societe Francaise d’Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clin Cancer Res 18(7):2001–2011PubMedCrossRefGoogle Scholar
  59. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61(3):215–225PubMedCrossRefGoogle Scholar
  60. Kluwe L, Hagel C, Tatagiba M, Thomas S, Stavrou D, Ostertag H, …, Mautner VF (2001) Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J Neuropathol Exp Neurol 60(9):917–920CrossRefGoogle Scholar
  61. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, …, Hartmann C (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118(3):401–405PubMedCrossRefGoogle Scholar
  62. Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, …, Kulozik AE (2010) Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 28(19):3182–3190PubMedCrossRefGoogle Scholar
  63. Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D et al (2015) Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 129:669–678PubMedCrossRefGoogle Scholar
  64. Kumar A, Pathak P, Purkait S, Faruq M, Jha P, Mallick S, …, Sarkar C (2015) Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas. Cancer Genet 208(3):91–95PubMedCrossRefGoogle Scholar
  65. Lin A, Rodriguez FJ, Karajannis MA, Williams SC, Legault G, Zagzag D, …, Bar EE (2012) BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549. J Neuropathol Exp Neurol 71(1):66–72CrossRefGoogle Scholar
  66. Listernick R, Louis DN, Packer RJ, Gutmann DH (1997) Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 41(2):143–149PubMedCrossRefGoogle Scholar
  67. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, …, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109PubMedPubMedCentralCrossRefGoogle Scholar
  68. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820PubMedCrossRefGoogle Scholar
  69. Macaulay RJ, Jay V, Hoffman HJ, Becker LE (1993) Increased mitotic activity as a negative prognostic indicator in pleomorphic xanthoastrocytoma: case report. J Neurosurg 79(5):761–768PubMedCrossRefGoogle Scholar
  70. MacDonald TJ, Arenson EB, Ater J, Sposto R, Bevan HE, Bruner J, …, O’Brien R (2005) Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma. Cancer 104(12):2862–2871PubMedCrossRefGoogle Scholar
  71. Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stütz AM, …, Zhang X (2014) Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506(7489):445–450Google Scholar
  72. Matsumura H, Takimoto H, Shimada N, Hirata M, Ohnishi T, Hayakawa T (1998) Glioblastoma following radiotherapy in a patient with tuberous sclerosis. Neurol Med Chir 38(5):287–291CrossRefGoogle Scholar
  73. Maxwell M, Naber SP, Wolfe HJ et al (1990) Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Investig 86(1):131–140PubMedPubMedCentralCrossRefGoogle Scholar
  74. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, …, Yung WA (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061–1068Google Scholar
  75. Medlock MD (2001) Supratentorial astrocytoma. In: Keating RF, Goodrich IT, Packer RI (eds) Tumors of the pediatric central nervous system. Thieme Medical Publishers, New YorkGoogle Scholar
  76. Merchant TE, Conklin HM, Wu S, Lustig RH, Xiong X (2009) Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol 27(22):3691–3697PubMedPubMedCentralCrossRefGoogle Scholar
  77. Miller DC, Lang FF, Epstein FJ (1993) Central nervous system gangliogliomas: part 1: pathology. J Neurosurg 79(6):859–866PubMedCrossRefPubMedCentralGoogle Scholar
  78. Modena P, Buttarelli FR, Miceli R, Piccinin E, Baldi C, Antonelli M, …, Sardi I (2012) Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis. Neuro Oncol 14(11):1346–1356PubMedPubMedCentralCrossRefGoogle Scholar
  79. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, …, Barnholtz-Sloan JS (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 17(Suppl 4):iv1–iv62PubMedPubMedCentralCrossRefGoogle Scholar
  80. Pahapill PA, Ramsay DA, Del Maestro RF (1996) Pleomorphic xanthoastrocytoma: case report and analysis of the literature concerning the efficacy of resection and the significance of necrosis. Neurosurgery 38:822–828PubMedCrossRefPubMedCentralGoogle Scholar
  81. Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, …, Reimand J (2015) Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27(5):728–743Google Scholar
  82. Palma L, Guidetti B (1985) Cystic pilocytic astrocytomas of the cerebral hemispheres: surgical experience with 51 cases and long-term results. J Neurosurg 62(6):811–815PubMedCrossRefPubMedCentralGoogle Scholar
  83. Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y, …, White E (2014) C11orf95–RELA fusions drive oncogenic NF-[kgr] B signalling in ependymoma. Nature 506(7489):451–455PubMedPubMedCentralCrossRefGoogle Scholar
  84. Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, …, Olivi A (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812PubMedPubMedCentralCrossRefGoogle Scholar
  85. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, …, Lowe J (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28(18):3061–3068PubMedPubMedCentralCrossRefGoogle Scholar
  86. Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, …, Ahmadi R (2008) BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 118(5):1739–1749PubMedPubMedCentralCrossRefGoogle Scholar
  87. Pollack IF (1994) Brain tumors in children. N Engl J Med 331(22):1500–1507PubMedCrossRefPubMedCentralGoogle Scholar
  88. Pollack IF (2008) Supratentorial hemispheric gliomas. In: Albright AL, Pollack IF, Adelson PD (eds) Principles and practice of pediatric neurosurgery, 2nd edn. Thieme Medical Publishers, New York/Stuttgart, pp 511–530Google Scholar
  89. Pollack IF, Claassen D, al-Shboul Q, Janosky JE, Deutsch M (1995) Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J Neurosurg 82(4):536–547PubMedCrossRefPubMedCentralGoogle Scholar
  90. Pollack IF, Hamilton RL, Burgeretal PC (2010) Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children’s Oncology Group. J Neuro-Oncol 99(2):155–163CrossRefGoogle Scholar
  91. Puget S, Philippe C, Bax DA, Job B, Varlet P, Junier MP, …, Roujeau T (2012) Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS One 7(2):e30313PubMedPubMedCentralCrossRefGoogle Scholar
  92. Qaddoumi I, Sultan I, Gajjar A (2009) Outcome and prognostic features in pediatric gliomas. Cancer 115(24):5761–5770PubMedPubMedCentralCrossRefGoogle Scholar
  93. Qu HQ, Jacob K, Fatet S, Ge B, Barnett D, Delattre O, …, Garami M (2010) Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro Oncol 12(2):153–163PubMedPubMedCentralCrossRefGoogle Scholar
  94. Raghavan R, Balani J, Perry A, Margraf L, Vono MB, Cai DX, …, White CL (2003) Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol 62(5):530–537CrossRefGoogle Scholar
  95. Ramkissoon LA, Horowitz PM, Craig JM, Ramkissoon SH, Rich BE, Schumacher SE, …, Tabak B (2013) Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci 110(20):8188–8193CrossRefGoogle Scholar
  96. Rao AAN, Laack NN, Giannini C, Wetmore C (2010) Pleomorphic xanthoastrocytoma in children and adolescents. Pediatr Blood Cancer 55:290–294PubMedCrossRefPubMedCentralGoogle Scholar
  97. Rizzo D, Ruggiero A, Martini M, Rizzo V, Maurizi P, Riccardi R (2015) Molecular biology in pediatric high-grade glioma: impact on prognosis and treatment. Biomed Res Int 2015:215135PubMedPubMedCentralGoogle Scholar
  98. Roach ES, FJ DM, Kandt RS, Northrup H (1999) Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 14(6):401–407PubMedCrossRefPubMedCentralGoogle Scholar
  99. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, …, Kunii K (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340(6132):626–630PubMedPubMedCentralCrossRefGoogle Scholar
  100. Rorke LB, Gilles FH, Davis RL, Becker LE (1985) Revision of the World Health Organization classification of brain tumors for childhood brain tumors. Cancer 56(S7):1869–1886PubMedCrossRefPubMedCentralGoogle Scholar
  101. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, …, Hovestadt V (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482(7384):226–231Google Scholar
  102. Shirzadi A, Danielpour M (2010) Pediatric ependymoma. In: Jallo G, Kothbauer K, Pradilla G (eds) Controversies in pediatric neurosurgery. Thieme Medical Publishing, New YorkGoogle Scholar
  103. Sievert AJ, Fisher MJ (2009) Pediatric low-grade gliomas. J Child Neurol 24(11):1397–1408PubMedPubMedCentralCrossRefGoogle Scholar
  104. Sinson G, Sutton LN, Yachnis AT, Duhaime AC, Schut L (1994) Subependymal giant cell astrocytomas in children. Pediatr Neurosurg 20(4):233–239PubMedCrossRefPubMedCentralGoogle Scholar
  105. Spostol R, Ertel IJ, Jenkin RDT, Boesel CP, Venes JL, Ortega JA, …, Hammond D (1989) The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. J Neuro Oncol 7(2):165–177CrossRefGoogle Scholar
  106. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, …, Curschmann J (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMedCrossRefGoogle Scholar
  107. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, …, Kool M (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22(4):425–437Google Scholar
  108. Taratuto AL, Pomata H, Sevlever G, Gallo G, Monges J (1995) Dysembryoplastic neuroepithelial tumor: morphological, immunocytochemical, and deoxyribonucleic acid analyses in a pediatric series. Neurosurgery 36(3):474–481PubMedGoogle Scholar
  109. Tatevossian RG, Tang B, Dalton J, Forshew T, Lawson AR, Ma J, …, Baker SJ (2010) MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathol 120(6):731–743PubMedPubMedCentralCrossRefGoogle Scholar
  110. Taylor KR, Vinci M, Bullock AN, Jones C (2014) ACVR1 mutations in DIPG: lessons learned from FOP. Cancer Res 74(17):4565–4570PubMedPubMedCentralCrossRefGoogle Scholar
  111. Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP, …, Snodgrass K (2015) Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neuro Oncol 121(3):557–563PubMedPubMedCentralCrossRefGoogle Scholar
  112. Tice H, Barnes PD, Goumnerova L, Scott RM, Tarbell NJ (1993) Pediatric and adolescent oligodendrogliomas. Am J Neuroradiol 14(6):1293–1300PubMedPubMedCentralGoogle Scholar
  113. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, …, Alexe G (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110PubMedPubMedCentralCrossRefGoogle Scholar
  114. Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R, …, Pollack I (2012) A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol 123(5):727–738PubMedPubMedCentralCrossRefGoogle Scholar
  115. Watanabe Y, Oki S, Migita K, Isobe N, Okazaki T, Nabika S (2003) A case of subependymal giant cell astrocytoma not associated with tuberous sclerosis. No Shinkei Geka Neurol Surg 31(5):543–548Google Scholar
  116. Wimmer K, Eckart M, Meyer-Puttlitz B, Fonatsch C, Pietsch T (2002) Mutational and expression analysis of the NF1 gene argues against a role as tumor suppressor in sporadic pilocytic astrocytomas. J Neuropathol Exp Neurol 61(10):896–902PubMedCrossRefPubMedCentralGoogle Scholar
  117. Wisoff JH, Sanford RA, Heier LA, Sposto R, Burger PC, Yates AJ, …, Kun LE (2011) Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children’s Oncology Group. Neurosurgery 68(6):1548–1555PubMedCrossRefPubMedCentralGoogle Scholar
  118. Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, …, Jones DT (2011) Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20(2):143–157PubMedPubMedCentralCrossRefGoogle Scholar
  119. Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, …, Easton J (2014) The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nature Genet 46(5):444Google Scholar
  120. Wu CT, Tsay PK, Jaing TH, Chen SH, Tseng CK, Jung SM (2016) Oligodendrogliomas in children: clinical experiences with 20 patients. J Pediatr Hematol Oncol 38(7):555–558PubMedCrossRefPubMedCentralGoogle Scholar
  121. Yu J, Deshmukh H, Gutmann RJ, Emnett RJ, Rodriguez FJ, Watson MA, …, Gutmann DH (2009) Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology 73(19):1526–1531PubMedPubMedCentralCrossRefGoogle Scholar
  122. Zacharoulis S, Moreno L (2009) Ependymoma: an update. J Child Neurol 24(11):1431–1438PubMedCrossRefPubMedCentralGoogle Scholar
  123. Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A, …, Hawkins C (2010) Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor α and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 28(8):1337–1344PubMedCrossRefPubMedCentralGoogle Scholar
  124. Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B et al (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45(6):602–612PubMedPubMedCentralCrossRefGoogle Scholar
  125. Zong H, Parada LF, Baker SJ (2015) Cell of origin for malignant gliomas and its implication in therapeutic development. Cold Spring Harb Perspect Biol 7(5):a020610PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Justin Cohen
    • 1
  • Sergui Bannykh
    • 2
  • Joshua Breunig
    • 3
  • Moise Danielpour
    • 1
  1. 1.Department of NeurosurgeryCedars Sinai Medical CenterLos AngelesUSA
  2. 2.Department of PathologyCedars Sinai Medical CenterLos AngelesUSA
  3. 3.Department of Biomedical SciencesRegenerative Medicine Institute, Cedars Sinai Medical CenterLos AngelesUSA

Section editors and affiliations

  • James Thomas Rutka
    • 1
  1. 1.The Arthur and Sonia Labatt Brain Tumour Research CentreThe Hospital for Sick Children, The University of TorontoTorontoUSA

Personalised recommendations